Logo

Regulus Raises $49.2M in Public Offering

Jul 25, 2013
Premium

Regulus Therapeutics this week said that it has completed its previously announced public stock offering of roughly 5.1 million shares at $9.50 a share. The company also said that the overallotment option to buy an additional 675,000 shares has been fully exercised by the offering’s underwriters.

Gross proceeds of the offering were $49.2 million.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
miRNA
Regulus
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.